0001477449-24-000109.txt : 20240506 0001477449-24-000109.hdr.sgml : 20240506 20240506160521 ACCESSION NUMBER: 0001477449-24-000109 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240504 FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cave James L. CENTRAL INDEX KEY: 0002019394 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 24917473 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 3 1 wk-form3_1715025901.xml FORM 3 X0206 3 2024-05-04 0 0001477449 Teladoc Health, Inc. TDOC 0002019394 Cave James L. C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203 PURCHASE NY 10577 0 1 0 0 INTERIM CAO Common Stock 10448 D Employee Stock Option (right to buy) 151.53 2031-10-31 Common Stock 1493 D Restricted Stock Units Common Stock 220 D Restricted Stock Units Common Stock 1356 D Restricted Stock Units Common Stock 1917 D Restricted Stock Units Common Stock 1001 D Restricted Stock Units Common Stock 9301 D Restricted Stock Units Common Stock 15000 D The option vested as to 25% of the shares on November 1, 2022. The remainder of the shares vest in 36 substantially equal monthly installments thereafter. On November 1, 2021, the reporting person was granted 660 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. On April 1, 2022, the reporting person was granted 4,067 restricted stock units, vesting one-third on March 1, 2023, with the remainder vesting in eight substantially equal quarterly installments thereafter. On June 1, 2022, the reporting person was granted 4,598 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. On June 1, 2022, the reporting person was granted 4,002 restricted stock units, vesting in four substantially equal semiannual installments beginning on the six-month anniversary of the grant date. On March 3, 2023, the reporting person was granted 13,951 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. On March 1, 2024, the reporting person was granted 15,000 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. Exhibit 24 -- Power of Attorney /s/ Adam C. Vandervoort, Attorney-in-Fact 2024-05-06 EX-24 2 exhibit24.txt EX-24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Adam C. Vandervoort, Jonathan Dorfman and Seth Lowinger, or any of them signing singly, and with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to: 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID Application and/or Passphrase Update Application and/or Request to Convert from Paper to Electronic Filer, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any rule or regulation of the SEC; 2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Teladoc Health, Inc., a Delaware corporation (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder; 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of April, 2024. Signature: /s/ James L. Cave Print Name: James L. Cave